Bipolar Disorder Therapeutics Drugs Market Report 2025 (Global Edition)

Global Bipolar Disorder Therapeutics Drugs Market Report 2025 Market Size Split by Drug Class (Mood Stabilizers, Antipsychotic Drugs, Antidepressant Drugs, Other Drugs), by Mechanism of Action (Select...

Bipolar Disorder Therapeutics Drugs Market Report Description

We have various report editions of Bipolar Disorder Therapeutics Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Bipolar Disorder Therapeutics Drugs Market Insights Video

Competitive Landscape of the Bipolar Disorder Therapeutics Drug Market

The market for medications for bipolar disorder is competitive and includes major manufacturers like Johnson & Johnson, AstraZeneca, Eli Lilly, and GlaxoSmithKline. These businesses concentrate on creating cutting-edge treatments to satisfy growing demand, such as mood stabilizers, antipsychotics, and combination medications. Intense R&D, ongoing innovation, and strategic partnerships are what fuel market competition. Furthermore, branded medications are under pressure to lower their prices due to the rise of biosimilars and generics. Additionally, businesses are growing in new markets to broaden their worldwide reach.

In April 2022, Leading biopharmaceutical company Intra-Cellular Therapies, well-known for its treatments, declared that it had received approval for the increased dosage of CAPLYTA. This medication, which has demonstrated effectiveness in treating bipolar illnesses, will now be offered in capsule form in dosages of 10.5 mg and 21 mg. (Source: https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-fda-approval-new-dosage ) In April 2022, The US Food and Drug Administration (FDA) authorized IGALMI (dexmedetomidine) sublingual film for the acute management of agitation linked to adult bipolar I or II illness or schizophrenia, according to a statement released by BioXcel Therapeutics, Inc. (Source: https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-fda-approval-igalmitm) In December 2021, The FDA approved CAPLYTA as a monotherapy and as an adjuvant Valproate or lithium medication for the management of depressive episodes linked to bipolar I or II disorder in adults, according to a statement released today by Intra-Cellular Therapies, Inc. This biopharmaceutical company specializes in the development and commercialization of therapeutics for disorders of the central nervous system (CNS). (Source: https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-us-fda-approval-caplytar) In June 2021, Alkermes PLC created LYBALVITM, a therapeutic medication that combines olanzapine and samidorphan to treat bipolar I illness in adults. Following FDA (Food and Drug Administration) approval in the United States, it will be marketed as an over-the-counter medication for the treatment of bipolar disorder. (Source: https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-fda-approval-lybalvitm-treatment)

Top Companies Market Share in Bipolar Disorder Therapeutics Drugs Industry: (In no particular order of Rank)

• AstraZeneca
• Bristol-Myers Squibb Company
• Allergan plc.
• Johnson & Johnson
• Eli Lilly and Company
• Astellas Pharma Inc.
• GlaxoSmithKline plc.
• Novartis International AG.
• Gedeon Richter Plc
• AbbVie Inc.
• Pfizer Inc.
• Janssen Pharmaceutica N.V.
• Validus Pharmaceuticals LLC
• Otsuka America Pharmaceutical Inc.
• Sumitomo Dainippon Pharma Co. Ltd.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Bipolar Disorder Therapeutics Drug Market

Which Region Dominates the Bipolar Disorder Therapeutics Drug Market in 2024?

According to Cognitive Market Research, North America currently dominates the Bipolar Disorder Therapeutics Drugs market, and the region is expected to have significant growth during the projected period. The market for medications used to treat bipolar disorder is expected to increase significantly in North America for a number of reasons. Because bipolar disorder is so common in the area and mental health is becoming less stigmatized, more people are seeking treatment. Efficient treatment of the illness is made possible by a sophisticated healthcare system and easy access to a variety of treatment alternatives. Pharmaceutical businesses also continue to engage in research and development with the goal of expanding and innovating therapeutic choices. Insurance coverage and supportive government regulations for mental health treatments also contribute to the North American market's expansion.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). The growing prevalence of bipolar illness and increased awareness of mental health issues would propel the expansion of the bipolar disorder therapeutics drug market in the Asia Pacific region. Early identification and treatment are becoming possible due to the expansion of the healthcare system and the availability of mental health services. Furthermore, societal changes that acknowledge and address mental health issues are motivating more people to get treatment. Improved access to cutting-edge treatment choices is another result of the region's expanding economy and healthcare investments. Furthermore, government programs that are designed to improve mental health services will help this region's market grow.

The current report Scope analyzes Bipolar Disorder Therapeutics Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Bipolar Disorder Therapeutics Drugs

According to Cognitive Market Research, the global Bipolar Disorder Therapeutics Drug market size was estimated at USD 6124.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 2449.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.7% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Bipolar Disorder Therapeutics Drug market with a market size of USD 1932.89 million in 2024 and is projected to grow at a CAGR of 1.5% during the forecast period. In the U.S. in the pharmaceutical industry, ongoing research and development promotes the creation of novel, more potent drugs.
• The Canadian Bipolar Disorder Therapeutics Drug market had a market share of USD 293.98 million in 2024 and is projected to grow at a CAGR of 2.5% during the forecast period. In Canada, patients are encouraged to seek assistance by government efforts that raise awareness of mental health issues.
• The Mexico Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 2.2% during the forecast period, with a market size of USD 222.93 million in 2024.

Europe Bipolar Disorder Therapeutics Drugs

According to Cognitive Market Research, the global Bipolar Disorder Therapeutics Drug market size was estimated at USD 6124.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 1837.35 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.0% from 2024 to 2031.

• The United Kingdom Bipolar Disorder Therapeutics Drug market had a market share of USD 308.67 million in 2024 and is projected to grow at a CAGR of 2.8% during the forecast period. In the UK, the number of bipolar disorder cases reported is increasing as a result of improved diagnostic procedures.
• The France Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 1.2% during the forecast period, with a market size of USD 169.04 million in 2024.
• According to Cognitive Market Research, the German Bipolar Disorder Therapeutics Drug market size was valued at USD 363.80 million in 2024 and is projected to grow at a CAGR of 2.2% during the forecast period. Germany places a strong focus on mental health research, which helps to create novel treatments.
• The Italy Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 1.4% during the forecast period, with a market size of USD 158.01 million in 2024.
• The Russia Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 1.0% during the forecast period, with a market size of USD 284.79 million in 2024.
• The Spain Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 1.1% during the forecast period with a market size of USD 150.66 million in 2024
• The Luxembourg Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 2.1% during the forecast period, with a market size of USD 56.96 million in 2024.
• The Portugal Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 1.8% during the forecast period, with a market size of USD 38.58 million in 2024.
• The Greece Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 2.3% during the forecast period, with a market size of USD 22.05 million in 2024.
• The Rest of Europe's Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 0.7% during the forecast period, with a market size of USD 284.79 million in 2024.

Asia Pacific Bipolar Disorder Therapeutics Drugs

According to Cognitive Market Research, the global Bipolar Disorder Therapeutics Drug market size was estimated at USD 6124.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 1408.64 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2031.

• According to Cognitive Market Research, the China Bipolar Disorder Therapeutics Drug market size was valued at USD 633.89 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. Bipolar Disorder Therapeutics Drug surged in China due to the demand for efficient mental health care as a result of stress-related problems brought on by rapid urbanization.
• The Japan Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 194.39 million in 2024.
• The India Bipolar Disorder Therapeutics Drug market had a market share of USD 169.04 million in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period. In India, patients are more likely to seek professional assistance when attitudes around mental health are changing.
• The South Korean Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 4.6% during the forecast period, with a market size of USD 140.86 million in 2024.
• The Australian Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 73.25 million in 2024.
• The South East Asia Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 97.20 million in 2024.
• The Rest of Asia Pacific Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 5.3% during the forecast period, with a market size of USD 100.01 million in 2024.

South America Bipolar Disorder Therapeutics Drugs

According to Cognitive Market Research, the global Bipolar Disorder Therapeutics Drug market size was estimated at USD 6124.5 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 306.23 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.9% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Bipolar Disorder Therapeutics Drug market size was valued at USD 131.06 million in 2024 and is projected to grow at a CAGR of 3.5% during the forecast period. Bipolar Disorder Therapeutics Drugs flourished in Brazil due to collaboration with international companies, making cutting-edge treatments more accessible.
• Argentina's Bipolar Disorder Therapeutics Drug market had a market share of USD 51.45 million in 2024 and is projected to grow at a CAGR of 3.8% during the forecast period. In Argentina, the development of digital tools for tracking and treating mental health issues.
• Colombia's Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD 27.25 million in 2024.
• Peru's Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 3.1% during the forecast period, with a market size of USD 25.11 million in 2024.
• Chile's Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD 22.05 million in 2024.
• The Rest of Latin America's Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 2.0% during the forecast period, with a market size of USD 49.30 million in 2024.

Middle East Bipolar Disorder Therapeutics Drugs

According to Cognitive Market Research, the global Bipolar Disorder Therapeutics Drug market size was estimated at USD 6124.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 122.49 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031..

• The GCC Countries Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 52.43 million in 2024. Bipolar Disorder Therapeutics Drug sales flourish in GCC countries due to the substantial expenditures in healthcare infrastructure to improve access to mental health services, such as treatment for bipolar illness.
• The Egypt Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 3.5% during the forecast period, with a market size of USD 12.86 million in 2024.
• The South African Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 19.35 million in 2024. Bipolar Disorder, Therapeutics Drug sales flourished in South Africa due to mental health problems that high rates of trauma and violence can bring on.
• The Turkey Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 2.7% during the forecast period, with a market size of USD 10.53 million in 2024.
• The Nigeria Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 2.3% during the forecast period, with a market size of USD 12.86 million in 2024.
• The Rest of the MEA Bipolar Disorder Therapeutics Drug market is projected to witness growth at a CAGR of 2.2% during the forecast period, with a market size of USD 14.45 million in 2024.

Bipolar Disorder Therapeutics Drugs Market Analysis

How are Segments Performing in the Global Bipolar Disorder Therapeutics Drug Market?

Bipolar Disorder Therapeutics Drug Market Drug Class Segment Analysis

According to Cognitive Market Research, mood stabilizers are likely to dominate the Bipolar Disorder Therapeutics Drug Market over the forecast period. The efficacy of mood stabilizers in controlling and averting the mood swings associated with bipolar disease makes them a vital component of the market for drugs used to treat bipolar disorder. Many people are prescribed medications such as lamotrigine, valproate, and lithium to regulate their mood and lessen the frequency and intensity of manic and depressive episodes. More people are seeking long-term, effective treatment alternatives as a result of rising diagnosis rates and increased knowledge of the disorder, which supports the need for mood stabilizers. The market expansion in this sector is further supported by continuous research into novel formulations and combinations, which increases their attractiveness.

Antipsychotic drugs are the fastest-growing segment in the Bipolar Disorder Therapeutics Drug Market. Antipsychotic medications are used as a temporary remedy for bipolar disorder to manage psychotic symptoms such as mania, hallucinations, and delusions. Both acute mania and severe depression may present with these symptoms. Antipsychotics such as lurasidone, olanzapine, aripiprazole, and cariprazine are increasingly used to treat acute manic psychosis. Thus, the segmental development will be complemented by an increase in cases with psychotic symptoms. Additionally, the growing emphasis on combination therapy for bipolar disorder will accelerate market expansion. Mood stabilizers and other pharmaceuticals are frequently used in conjunction with antipsychotic treatments, which is anticipated to fuel market expansion.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Bipolar Disorder Therapeutics Drugs Industry. Request a Free Sample PDF!

Bipolar Disorder Therapeutics Drug Market Mechanism of Action Segment Analysis

According to Cognitive Market Research, the selective serotonin reuptake inhibitors segment holds the largest share of the market. The market for drugs that treat bipolar disorder depends heavily on selective serotonin reuptake inhibitors (SSRIs), particularly in the therapy of severe depression. These drugs, which include sertraline and fluoxetine, function by boosting the brain's serotonin levels, which elevates mood and lessens depressive symptoms. Although SSRIs are frequently used for depression, their usage in the treatment of bipolar illness is handled carefully because of the possibility that they could trigger manic episodes. Healthcare professionals are increasingly considering SSRIs as part of combination therapy as bipolar disorder becomes more well-recognized, which is fueling the market's demand for these medications.

In the Bipolar Disorder Therapeutics Drug Market, benzodiazepines have been expanding at a rapid pace. The significance of benzodiazepines in treating acute anxiety and agitation linked to bipolar episodes is becoming more widely acknowledged in the bipolar disorder therapeutics drug market. The neurotransmitter gamma-aminobutyric acid (GABA) is enhanced at GABA-A receptors by these drugs, which include lorazepam and clonazepam. This results in sedative, anxiolytic, and muscle-relaxant effects. Benzodiazepines work well for temporary pain but worries about tolerance and reliance frequently limit their use. Their continued applicability in bipolar disorder treatment plans is attributed to the fact that they are commonly used as supplemental therapy to manage acute symptoms.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion